Search

Your search keyword '"Penson D"' showing total 172 results
Start Over Author "Penson D"
172 results on '"Penson D"'

1. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades

Author

Eifler, J. B., Alvarez, J., Koyama, T., Conwill, R. M., Ritch, C. R., Hoffman, K. E., Resnick, M. J., Penson, D. F., Barocas, D. A., Albertsen, Peter C., Cooperberg, Matthew R., Goodman, Michael, Greenfield, Sheldon, Hamilton, Ann, Hoffman, Richard M., Kaplan, Sherrie H., Paddock, Lisa, Stanford, Janet L., Stroup, Antoinette M., and Wu, Xiao-Cheng

Published
2017
Full Text
View/download PDF

3. Reply by Authors - Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer

Author

Klotz, L., Pavlovich, C.P., Chin, J., Hatiboglu, G., Koch, M., Penson, D., Raman, S., Oto, A., Futterer, J.J., Serrallach, M., Relle, J., Lotan, Y., Heidenreich, A., Bonekamp, D., Haider, M., Tirkes, T., Arora, S., Macura, K.J., Costa, D.N., Persigehl, T., Pantuck, A.J., Bomers, J., Burtnyk, M., Staruch, R., Eggener, S., Klotz, L., Pavlovich, C.P., Chin, J., Hatiboglu, G., Koch, M., Penson, D., Raman, S., Oto, A., Futterer, J.J., Serrallach, M., Relle, J., Lotan, Y., Heidenreich, A., Bonekamp, D., Haider, M., Tirkes, T., Arora, S., Macura, K.J., Costa, D.N., Persigehl, T., Pantuck, A.J., Bomers, J., Burtnyk, M., Staruch, R., and Eggener, S.

Abstract

Contains fulltext : 232934.pdf (Publisher’s version ) (Closed access)

Published
2021

8. Pivotal trial of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Two-year follow-up

Author

Klotz, L.H., primary, Chin, J., additional, Hatiboglu, G., additional, Koch, M., additional, Penson, D., additional, Pavlovich, C., additional, Raman, S., additional, Oto, A., additional, Fütterer, J., additional, Relle, J., additional, Lotan, Y., additional, Heidenreich, A., additional, Serrallach, M., additional, Haider, M., additional, Bonekamp, D., additional, Tirkes, T., additional, Arora, S., additional, Pantuck, A., additional, Zagaja, G., additional, Sedelaar, M., additional, Macura, K., additional, Costa, D., additional, Persigehl, T., additional, and Eggener, S., additional

Published
2020
Full Text
View/download PDF

11. Reply by Authors

Author

Ritch, C. R., primary, Cookson, M. S., additional, Clark, P. E., additional, Chang, S. S., additional, Fakhoury, K., additional, Ralls, V., additional, Thu, M. H., additional, Penson, D. F., additional, Smith, J. A., additional, and Silver, H. J., additional

Published
2019
Full Text
View/download PDF

12. Pivotal study of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Preliminary results

Author

Klotz, L.H., primary, Hatiboglu, G., additional, Fütterer, J., additional, Persigehl, T., additional, Serrallach, M., additional, Koch, M., additional, Pavlovich, C., additional, Lotan, Y., additional, Raman, S., additional, Relle, J., additional, Zagaja, G., additional, Haider, M.A., additional, Arora, S.S., additional, Staruch, R.M., additional, Burtnyk, M.A., additional, Costa, D., additional, Oto, A., additional, Tirkes, T., additional, Sedelaar, J.P.M., additional, Bonekamp, D., additional, Heidenreich, A., additional, Penson, D., additional, Chin, J., additional, and Eggener, S., additional

Published
2019
Full Text
View/download PDF

14. Association entre la qualité de vie liée à la santé (qdv) et les signes cliniques du cancer de prostate résistant à la castration non métastatique (cprcnm) : résultats de l’étude prosper

Author

Villers, A., primary, Attard, G., additional, Saad, F., additional, Tombal, B., additional, Hussein, M., additional, Sternberg, C., additional, Phung, D., additional, Morlock, R., additional, Modelska, K., additional, Reisman, A., additional, Ivanescu, C., additional, and Penson, D., additional

Published
2018
Full Text
View/download PDF

15. Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study

Author

Tombal, B., primary, Hussain, M., additional, Penson, D., additional, Attard, G., additional, Sternberg, C.N., additional, Phung, D., additional, Morlock, R., additional, Modelska, K., additional, Ramaswamy, K., additional, Ivanescu, C., additional, and Saad, F., additional

Published
2018
Full Text
View/download PDF

19. 472 - Pivotal study of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Preliminary results

Author

Klotz, L.H., Hatiboglu, G., Fütterer, J., Persigehl, T., Serrallach, M., Koch, M., Pavlovich, C., Lotan, Y., Raman, S., Relle, J., Zagaja, G., Haider, M.A., Arora, S.S., Staruch, R.M., Burtnyk, M.A., Costa, D., Oto, A., Tirkes, T., Sedelaar, J.P.M., Bonekamp, D., Heidenreich, A., Penson, D., Chin, J., and Eggener, S.

Published
2019
Full Text
View/download PDF

24. Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy

Author

Kavitt, R. T., Penson, D. F., and Vaezi, M. F.

Subjects
Decision Trees, Anti-Inflammatory Agents, Eosinophilic Esophagitis, Dilatation, Tennessee, Article, Androstadienes, Hospitalization, Costs and Cost Analysis, Esophageal Stenosis, Fluticasone, Humans, Endoscopy, Digestive System, Metered Dose Inhalers, Deglutition Disorders
Abstract

Eosinophilic esophagitis (EoE) is an increasingly recognized clinical entity. The optimal initial treatment strategy in adults with EoE remains controversial. The aim of this study was to employ a decision analysis model to determine the less costly option between the two most commonly employed treatment strategies in EoE. We constructed a model for an index case of a patient with biopsy-proven EoE who continues to be symptomatic despite proton-pump inhibitor therapy. The following treatment strategies were included: (i) swallowed fluticasone inhaler (followed by esophagogastroduodenoscopy [EGD] with dilation if ineffective); and (ii) EGD with dilation (followed by swallowed fluticasone inhaler if ineffective). The time horizon was 1 year. The model focused on cost analysis of initial treatment strategies. The perspective of the healthcare payer was used. Sensitivity analyses were performed to assess the robustness of the model. For every patient whose symptoms improved or resolved with the strategy of fluticasone first followed by EGD, if necessary, it cost an average of $1078. Similarly, it cost an average of $1171 per patient if EGD with dilation was employed first. Sensitivity analyses indicated that initial treatment with fluticasone was the less costly strategy to improve dysphagia symptoms as long as the effectiveness of fluticasone remains at or above 0.62. Swallowed fluticasone inhaler (followed by EGD with dilation if necessary) is the more economical initial strategy when compared with EGD with dilation first.

Published
2012

27. What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study

Author

Oswald LB, Schumacher FA, Gonzalez BD, Moses KA, Penson DF, and Morgans AK

Subjects
decision making, focus groups, metastasis, prostate cancer, quality of life, Medicine (General), R5-920
Abstract

Laura B Oswald,1 Frank A Schumacher,2 Brian D Gonzalez,1 Kelvin A Moses,3 David F Penson,3,4 Alicia K Morgans2 1Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 3Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA; 4Department of Urology, VA Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC), Nashville, TN, USACorrespondence: Alicia K MorgansNorthwestern University Feinberg School of Medicine, 676 N. Saint Clair, Suite 850., Chicago, IL 60611, USATel +1312-695-2381Email Alicia.Morgans@northwestern.eduObjective: Metastatic prostate cancer (mPCa) patients often make complicated treatment decisions, yet decision aids to facilitate shared decision-making for mPCa are uncommon. To inform the development of patient-centered mPCa decision aids, we examined what mPCa survivors considered most important when making treatment decisions.Methods: Using an exploratory sequential approach, we conducted three focus groups with 14 advanced prostate cancer survivors (n=5, n=3, n=6 in each group) to identify considerations for making treatment decisions. Focus groups were audio-recorded and transcribed, and we identified qualitative themes. We then developed a quantitative survey to assess the importance of each theme and administered the survey to mPCa survivors (N=100). We used relative frequencies to determine the most strongly endorsed items and chi-squared and Fisher’s exact tests to assess associations with participant characteristics.Results: Focus groups yielded 11 themes, and the resulting survey included 20 items. The most strongly endorsed mPCa treatment considerations were: relying on physician’s treatment recommendations (79% strongly agree); wanting to feel well enough to spend quality time with loved ones (72% strongly agree); the importance of dying in a manner consistent with one’s wishes (70% strongly agree); hoping to eliminate cancer completely (68% strongly agree); and optimizing treatment efficacy (65% strongly agree). Age, race, marital status, employment status, and self-reported health were related to how strongly men endorsed various considerations for mPCa treatment decision-making.Conclusion: We identified multiple considerations that mPCa survivors appraised when making treatment decisions. These data may inform the development of patient-centered decision aids for mPCa.Keywords: decision-making, focus groups, metastasis, prostate cancer, quality of life

Published
2020

28. Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE

Author

Moses, K. A., Moses, K. A., Paciorek, A. T., Penson, D. F., Carroll, P. R., Master, V. A., Moses, K. A., Moses, K. A., Paciorek, A. T., Penson, D. F., Carroll, P. R., and Master, V. A.

Abstract

Purpose Men diagnosed with prostate cancer have multiple options available for treatment. Previous reports have indicated a trend of differing modalities of treatment chosen by African American and white men. We investigated the role of ethnicity in primary treatment choice and how this affected overall and cancer-specific mortality. Methods By utilizing data abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), patients were compared by ethnicity, primary treatment, number of comorbidities, risk level according to modified D'Amico criteria, age, highest educational level attained, type of insurance, treatment facility, and perception of general health. Multinomial logistic regression analysis was performed to determine the effect of the tested variables on primary treatment and mortality. Results African American men were more likely to receive nonsurgical therapy than white men with equivalent disease characteristics. Whites were 48% less likely than African Americans to receive androgen deprivation therapy (ADT) compared with surgery (P = .02) and were 25% less likely than African Americans to receive radiation therapy compared with surgery (P = .08). Whites with low-risk disease were 71% less likely to receive ADT than African American men with similar disease (P = .01). Adjusted overall and prostate cancer–specific mortality were not significantly different between whites and African Americans (hazard ratios, 0.73 and 0.37, respectively). Risk level, type of treatment, and type of insurance had the strongest effects on risk of mortality. Conclusion There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. Additional research on the influence of patient/physician education and perception and the role that socioeconomic factors play in mortality from prostate cancer may be areas of focus for public health initiatives.

Published
2010

42. MP-09.19

Author

Roehrborn, C., primary, Penson, D., additional, Te, A., additional, Wei, J., additional, and Nuckolls, J., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results